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ICU

:   intensive care unit

ILD

:   interstitial lung disease

KL‐6

:   Krebs von den Lungen‐6

1. INTRODUCTION {#jmv26087-sec-0020}
===============

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) emerged in Wuhan (China) in December 2019 and was declared pandemic by the World Health Organization (WHO) in March 2020. It has been hypothesized that CD4‐ and CD8‐positive cells play a crucial role in defence against coronavirus, together with activated B cells producing specific antibodies and proinflammatory cytokines. Elevated serum concentrations of proinflammatory cytokines and oxidative stress mediators participate in lung injury, facilitating acute respiratory distress syndrome (ARDS) in severe patients. Host susceptibility and virus‐induced direct cytopathic effects against type I and II pneumocytes mediate lung damage.

Krebs von den Lungen‐6 (KL‐6) is a high molecular weight glycoprotein, elevated in serum of patients with interstitial lung diseases (ILDs), such as idiopathic pulmonary fibrosis and hypersensitivity pneumonitis. It is mainly produced by damaged or regenerating alveolar type II pneumocytes.[^1^](#jmv26087-bib-0001){ref-type="ref"} This mucin protein is recognized as a prognostic bioindicator of ILDs, predicting response to antifibrotic therapies.[^2^](#jmv26087-bib-0002){ref-type="ref"}, [^3^](#jmv26087-bib-0003){ref-type="ref"}, [^4^](#jmv26087-bib-0004){ref-type="ref"} It has also been proposed as a prognostic marker of ARDS: high KL‐6 concentrations have been demonstrated in ventilated patients and showed a correlation with risk of mortality.[^5^](#jmv26087-bib-0005){ref-type="ref"} KL‐6 serum levels in ARDS may reflect the alveolar epithelial cell damage induced by mechanical ventilatory support.[^5^](#jmv26087-bib-0005){ref-type="ref"} High peripheral levels of this protein have also been reported in *Legionella*, *Pneumocystis jivorecii* infections,[^6^](#jmv26087-bib-0006){ref-type="ref"}, [^7^](#jmv26087-bib-0007){ref-type="ref"} and measles‐associated pneumonia,[^8^](#jmv26087-bib-0008){ref-type="ref"} as well as in viral pneumonia.[^9^](#jmv26087-bib-0009){ref-type="ref"}

This preliminary study analyzed serum concentrations of KL‐6 for the first time in a population of hospitalized coronavirus disease (COVID‐19) patients to verify its potential as a prognostic biomarker of severity.

2. MATERIALS AND METHODS {#jmv26087-sec-0030}
========================

2.1. Study population {#jmv26087-sec-0040}
---------------------

Twenty‐two patients (median age \[interquartile range {IQR}\] 63 \[59‐68\] years, 16 males), hospitalized at Siena University Hospital with COVID‐19, were enrolled prospectively. Patients were divided into mild‐moderate and severe groups, according to respiratory impairment and clinical management. All patients in the severe group underwent intubation and mechanical ventilation in the COVID intensive care unit (ICU), while mild‐moderate patients (not requiring intubation) were hospitalized for pharmacological treatment and oxygen supplementation or noninvasive ventilation. Patients in the severe group included nine patients with bilateral diffuse interstitial pneumonia and three patients with focal bilateral pneumonia. The 12 mild‐moderate patients included three with bilateral diffuse pneumonia, one with monolateral pneumonia, and the other eight with focal bilateral pneumonia, all documented radiologically. Patients with pre‐existing ILDs, chronic obstructive lung disease, or concomitant infections were excluded from the study.

Twenty‐two healthy volunteers (median age \[IQR\] 54 \[29‐60\] years, six males) were also enrolled. They had no history of concomitant pathologies and were not on any medication. They had normal lung function test parameters and normal chest X‐ray.

All patients gave their written informed consent to the study. The study was approved by our local ethics committee (BIOBANCA‐MIU‐2010).

2.2. KL‐6 assay {#jmv26087-sec-0050}
---------------

Serum samples were obtained from all patients at hospital admission before any biological treatment or infusion of high‐dose intravenous steroids or invasive ventilation. Serum concentrations of KL‐6 (sKL‐6) were measured by KL‐6 reagent assay (Fujirebio Europe, UK), as previously reported.[^2^](#jmv26087-bib-0002){ref-type="ref"}, [^4^](#jmv26087-bib-0004){ref-type="ref"}, [^10^](#jmv26087-bib-0010){ref-type="ref"} The principle of the assay is agglutination of sialylated carbohydrate antigen in samples with KL‐6 monoclonal antibody by antigen--antibody reaction. The change in absorbance was measured to determine KL‐6 concentrations, which were expressed in U/mL.

2.3. Flow cytometry analysis {#jmv26087-sec-0060}
----------------------------

Blood samples were processed by flow cytometry using a panel of monoclonal antibodies (BD Multitest™ 6‐color TBNK; BD‐Biosciences, San Jose, CA), including fluorescein isothiocyanate‐labelled CD3, phycoerythrin‐labelled CD16 and CD56, PerCPCy5.5‐labelled CD45, PECy7‐labelled CD4, APC‐labelled CD19, and APCCy7‐labelled CD8, according to the manufacturer\'s instructions. At least 30 000 events were collected for each sample. Data were analyzed using DIVA software (BD‐Biosciences). Lymphocytes were phenotyped on the basis of forward (FSC) vs side (SSC) scatters and additional gating was applied using SSC vs CD45 to distinguish lymphocytes from cell debris. Specific panels were subsequently assessed to identify T lymphocytes, B lymphocytes, and natural killer (NK) cells. T lymphocyte subpopulations were gated to distinguish CD3^+^CD4^+^ (T‐helper), CD3^+^CD8^+^ (T‐cytotoxic), and CD3^−^ CD16^+^/56^+^ (NK).

2.4. Statistical analysis {#jmv26087-sec-0070}
-------------------------

The data did not show a normal distribution. One‐way analysis of variance nonparametric test (Kruskal--Wallis test) and Dunn test were used for multiple comparisons. The Mann--Whitney test was used to compare pairs of variables. The *χ* ^2^ test was used for categorical variables as appropriate. Immunological data were also compared between the severe and nonsevere groups, assessing areas under the receiver operating characteristic (ROC) curves (AUC). *P* \< .05 was considered statistically significant. Statistical analysis and graphic representation of the data were performed with GraphPad Prism 8.0 software.

3. RESULTS {#jmv26087-sec-0080}
==========

3.1. Study population {#jmv26087-sec-0090}
---------------------

Table [1](#jmv26087-tbl-0001){ref-type="table"} shows the main characteristics of our COVID‐19 population together with lymphocyte subset results and KL‐6 concentrations in serum, dividing patients into severe vs mild‐moderate groups on the basis of whether mechanical ventilation requirements.

###### 

Main characteristics of population including age (median \[IQR\]), sex (%), lymphocyte subsets, and KL‐6 concentrations at the hospital admission

  Parameters                            Severe cases (n = 12)   Nonsevere cases (n = 10)   *P*‐value
  ------------------------------------- ----------------------- -------------------------- -----------
  Age (median \[IQR\])                  62 \[60‐68\]            64 \[51‐64\]               .5761
  Sex, M/F                              9/3                     6/4                        .6517
  Lymphocyte subsets (median \[IQR\])                                                      
  CD45, cells/µL                        792 \[548‐1156\]        1039 \[655‐1612\]          .2268
  CD3%                                  73 \[65‐81\]            72 \[69‐73\]               .6504
  CD3, cells/µL                         495 \[406‐789\]         794 \[569‐1014\]           .1956
  CD4%                                  45 \[37‐54\]            40 \[39‐43\]               .2894
  CD4, cells/µL                         356 \[232‐533\]         458 \[342‐551\]            .4695
  CD8%                                  21 \[15‐33\]            29 \[25‐33\]               .4320
  CD8, cells/µL                         136 \[89‐307\]          333 \[217‐432\]            .1422
  CD19%                                 12 \[9‐21\]             15 \[12‐18\]               .5358
  CD19, cells/µL                        109 \[58‐139\]          135 \[113‐226\]            .1883
  NK cells %                            10 \[6‐13\]             14 \[9‐15\]                .1148
  NK, cells/µL                          74 \[32‐101\]           141 \[88‐205\]             .0449
  CD4/CD8                               2.3 \[1.1‐3.4\]         1.5 \[1.2‐1.8\]            .3402
  KL‐6, U/mL                            1021 \[473‐1909\]       293 \[197‐362\]            .0118

Abbreviation: IQR, interquartile range.
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The total number of lymphocytes (CD45^+^) was found to be depleted in all patients (median \[IQR\] 797 \[566‐1150\] cells/µL) and peripheral NK cells/µL were significantly higher in nonsevere patients than in the severe group (median \[IQR\] 141 \[88‐205\] vs 74 \[32‐101\]; *P* = .0449). ROC analysis distinguished these two groups with an AUC of 78.6% (95% confidence interval \[CI\]: 55‐100; *P* = .0425; Figure [1A](#jmv26087-fig-0001){ref-type="fig"}) and the best cut‐off value was 119 cells/µL (71% sensitivity and 92% specificity).

![A, Receiver operating characteristic (ROC) analysis of natural killer cells/µL between severe and nonsevere coronavirus disease (COVID‐19) patients. B, Krebs von den Lungen‐6 (KL‐6) concentrations in COVID‐19 patients and healthy controls. (*P* \< .05). C, ROC analysis of serum KL‐6 concentrations between severe and nonsevere COVID‐19 patients](JMV-9999-na-g001){#jmv26087-fig-0001}

KL‐6 serum concentrations were significantly higher in severe patients than the nonsevere group (median \[IQR\] 1021 \[473‐1909\] vs 293 \[197‐362\], *P* = .0118; Figure [1B](#jmv26087-fig-0001){ref-type="fig"}). ROC analysis distinguished severe and nonsevere patients according KL‐6 serum levels with AUC 82.4% (95% CI: 62‐100, *P* = .0129; Figure [1C](#jmv26087-fig-0001){ref-type="fig"}) and the best cut‐off value was 406.5 U/mL (83% sensitivity and 89% specificity).

When KL‐6 concentrations were compared between COVID‐19 patients and healthy controls, the latter showed serum concentrations of KL‐6 similar to those of nonsevere patients (median \[IQR\] 239 \[132‐371\] vs 293 \[197‐362\], *P* = .5277; Figure [1B](#jmv26087-fig-0001){ref-type="fig"}), while on the other hand, KL‐6 concentrations were significantly higher in severe patients than in healthy controls (median \[IQR\] 1021 \[473‐1909\] vs 239 \[132‐371\], *P* = .012; Figure [1B](#jmv26087-fig-0001){ref-type="fig"}).

4. DISCUSSION {#jmv26087-sec-0100}
=============

In this study, KL‐6 was analyzed for the first time in a population of patients with COVID‐19. Serum concentrations of KL‐6 were only elevated in severe patients admitted to the ICU and requiring intubation and mechanical ventilation for diffuse interstitial pneumonia, and not in mild‐moderate patients with less severe respiratory impairment. Patients with mild‐moderate COVID interstitial pneumonia showed serum concentrations of KL‐6 similar to those of healthy controls.

Although these results are preliminary (this was a monocentric study with a limited number of patients), they are of interest because KL‐6 emerged as a potential prognostic biomarker readily detected in serum of COVID‐19 patients and helpful for phenotyping patients according to disease severity.

This mucin protein has been widely studied in idiopathic pulmonary fibrosis and patients with ARDS but limited data have so far been available on its prognostic potential in infective pneumonia.[^1^](#jmv26087-bib-0001){ref-type="ref"}, [^5^](#jmv26087-bib-0005){ref-type="ref"}, [^9^](#jmv26087-bib-0009){ref-type="ref"} No data have hitherto been available on its pattern in coronavirus‐induced interstitial pneumonia. Our interest was aroused by the observation that this biomarker was correlated with prognosis in ILDs and ARDS, reflecting alveolar type I and type II pneumocyte damage. KL‐6 concentrations at peripheral blood level can reflect severe interstitial lung damage, epithelial lung alterations and regenerative processes secondary to SARS‐CoV‐2 infection. In this context, a further aim will be to perform a serial evaluation of KL‐6 in the follow‐up of COVID‐19 patients.

Another interesting finding, in line with previous studies on series of ILD and ARDS patients, was that KL‐6 showed potential as a prognostic biomarker of COVID‐19 pneumonia---patients with serum concentrations greater than 406 U/mL showed severe disease and a high risk of intubation. Likewise, Sato et al[^5^](#jmv26087-bib-0005){ref-type="ref"} reported median serum concentrations of KL‐6 of 537 U/mL in 28 patients with ARDS.

These results are worthy of further validation in a larger cohort to define the cut‐off value for identifying patients at high risk of severe respiratory failure. Moreover, these parameters may help clinicians establish correct timing of mechanical ventilation in this specific population. Lymphocyte depletion and decreased NK subsets in peripheral blood were accentuated in COVID‐19 patients[^11^](#jmv26087-bib-0011){ref-type="ref"} with severe interstitial pneumonia and high serum concentrations of KL‐6.

In conclusion, lymphocyte phenotyping including NK cell analysis and assay of KL‐6 in serum can help identify severe COVID‐19 patients. Serum concentrations of KL‐6 were only elevated in patients with severe pulmonary involvement, revealing a prognostic value and supporting the potential usefulness of KL‐6 measurement to evaluate COVID‐19 patients\' prognosis.
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